Molecular Classification and Intratumoral Heterogeneity of Gastric Adenocarcinoma

Overview

Journal Pathol Int

Specialty Pathology

Date 2024 Apr 23

PMID 38651937

Authors

Takeshi Kuwata

Affiliations

Soon will be listed here.

Abstract

Gastric cancers frequently harbor striking histological complexity and diversity between lesions as well as within single lesions, known as inter- and intratumoral heterogeneity, respectively. The latest World Health Organization Classification of Tumors designated more than 30 histological subtypes for gastric epithelial tumors, assigning 12 subtypes for gastric adenocarcinoma (GAD). Meanwhile, recent advances in genome-wide analyses have provided molecular aspects to the histological classification of GAD, and consequently revealed different molecular traits underlying these histological subtypes. Moreover, accumulating knowledge of comprehensive molecular profiles has led to establishing molecular classifications of GAD, which are often associated with clinical biomarkers for therapeutics and prognosis. However, most of our knowledge of GAD molecular profiles is based on inter-tumoral heterogeneity, and the molecular profiles underlying intratumoral heterogeneity are yet to be determined. In this review, recently established molecular classifications of GAD are introduced in the aspect of pathological diagnosis and are discussed in the context of intratumoral heterogeneity.

Citing Articles

Spatial and Temporal Tumor Heterogeneity in Gastric Cancer: Discordance of Predictive Biomarkers.

Lee H J Gastric Cancer. 2025; 25(1):192-209.

PMID: 39822175 PMC: 11739643. DOI: 10.5230/jgc.2025.25.e3.

Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma.

Kuwata T Pathol Int. 2024; 74(6):301-316.

PMID: 38651937 PMC: 11551831. DOI: 10.1111/pin.13427.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Bartley A, Washington M, Colasacco C, Ventura C, Ismaila N, Benson 3rd A . HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017; 35(4):446-464. DOI: 10.1200/JCO.2016.69.4836. View

Mathiak M, Warneke V, Behrens H, Haag J, Boger C, Kruger S . Clinicopathologic Characteristics of Microsatellite Instable Gastric Carcinomas Revisited: Urgent Need for Standardization. Appl Immunohistochem Mol Morphol. 2015; 25(1):12-24. PMC: 5147042. DOI: 10.1097/PAI.0000000000000264. View

Choi Y, Bae J, An J, Kwon I, Cho I, Shin H . Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis. J Surg Oncol. 2014; 110(2):129-35. DOI: 10.1002/jso.23618. View

Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W . Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52(7):797-805. DOI: 10.1111/j.1365-2559.2008.03028.x. View

Choi Y, Kim H, Shin S, Kim H, Lee J, Yang H . Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Ann Surg. 2018; 270(2):309-316. DOI: 10.1097/SLA.0000000000002803. View

Tougeron D, Fauquembergue E, Rouquette A, Le Pessot F, Sesboue R, Laurent M . Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol. 2009; 22(9):1186-95. DOI: 10.1038/modpathol.2009.80. View

Thuss-Patience P, Shah M, Ohtsu A, Van Cutsem E, Ajani J, Castro H . Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017; 18(5):640-653. DOI: 10.1016/S1470-2045(17)30111-0. View

Luchini C, Bibeau F, Ligtenberg M, Singh N, Nottegar A, Bosse T . ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019; 30(8):1232-1243. DOI: 10.1093/annonc/mdz116. View

10.

Apicella M, Corso S, Giordano S . Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget. 2017; 8(34):57654-57669. PMC: 5593674. DOI: 10.18632/oncotarget.14825. View

11.

Li W, Ng J, Wong C, Ng E, Yu J . Molecular alterations of cancer cell and tumour microenvironment in metastatic gastric cancer. Oncogene. 2018; 37(36):4903-4920. PMC: 6127089. DOI: 10.1038/s41388-018-0341-x. View

12.

Tan I, Ivanova T, Lim K, Ong C, Deng N, Lee J . Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011; 141(2):476-85, 485.e1-11. PMC: 3152688. DOI: 10.1053/j.gastro.2011.04.042. View

13.

Hoadley K, Yau C, Wolf D, Cherniack A, Tamborero D, Ng S . Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014; 158(4):929-944. PMC: 4152462. DOI: 10.1016/j.cell.2014.06.049. View

14.

Shah M, Shitara K, Ajani J, Bang Y, Enzinger P, Ilson D . Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023; 29(8):2133-2141. PMC: 10427418. DOI: 10.1038/s41591-023-02465-7. View

15.

Sun K, Jia K, Lv H, Wang S, Wu Y, Lei H . EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives. Front Oncol. 2020; 10:583463. PMC: 7769310. DOI: 10.3389/fonc.2020.583463. View

16.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

17.

Cristescu R, Lee J, Nebozhyn M, Kim K, Ting J, Wong S . Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015; 21(5):449-56. DOI: 10.1038/nm.3850. View

18.

Yagi S, Wakatsuki T, Yamamoto N, Chin K, Takahari D, Ogura M . Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. Gastric Cancer. 2018; 22(3):518-525. PMC: 6476840. DOI: 10.1007/s10120-018-0887-x. View

19.

Anderson A, Weaver A, Cummings P, Quaranta V . Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell. 2006; 127(5):905-15. DOI: 10.1016/j.cell.2006.09.042. View

20.

Zhang M, Dong Y, Liu H, Zhao S, Xuan Q, Wang Y . The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients. Sci Rep. 2016; 6:37933. PMC: 5124943. DOI: 10.1038/srep37933. View